CV Sciences (CVSI) Liabilities and Shareholders Equity (2010 - 2026)

CV Sciences has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $6.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 13.39% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 14.91% YoY) and the FY2025 annual result came in at $7.0 million, down 12.17% from the prior year.
• Liabilities and Shareholders Equity fell to $6.7 million in Q1 2026 per CVSI's latest filing, from $7.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $18.3 million in Q1 2022 and troughed at $341000.0 in Q3 2024.
• A 5-year average of $9.7 million and a median of $8.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity sank 96.46% in 2024, then soared 1951.32% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $12.7 million in 2022, then decreased by 27.76% to $9.2 million in 2023, then decreased by 13.84% to $7.9 million in 2024, then slipped by 12.17% to $7.0 million in 2025, then retreated by 3.45% to $6.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.7 million, $7.0 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.